

# Dan Atar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7905728/publications.pdf>

Version: 2024-02-01

272  
papers

56,360  
citations

<sup>23879</sup>  
60  
h-index

<sup>1256</sup>  
232  
g-index

291  
all docs

291  
docs citations

291  
times ranked

46068  
citing authors

#	ARTICLE	IF	CITATIONS
1	Apixaban versus Warfarin in Patients with Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 981-992.	13.9	7,537
2	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Heart Journal</i> , 2016, 37, 2893-2962.	1.0	5,689
3	ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.	1.0	5,034
4	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2010, 31, 2369-2429.	1.0	4,635
5	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>Europace</i> , 2016, 18, 1609-1678.	0.7	3,523
6	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2012, 33, 2719-2747.	1.0	3,144
7	Fourth universal definition of myocardial infarction (2018). <i>European Heart Journal</i> , 2019, 40, 237-269.	1.0	2,687
8	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). <i>European Heart Journal</i> , 2008, 29, 2388-2442.	1.0	2,656
9	Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.	1.2	2,558
10	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited) <i>Tj ETQq0 0 0 0 gBT / Overlock 10 T</i>	1.0	2,331
11	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. <i>Europace</i> , 2012, 14, 1385-1413.	0.7	2,319
12	The Effects of Climate Change on Cardiac Health. <i>Cardiology</i> , 2015, 131, 209-217.	0.6	1,123
13	Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2011, 365, 699-708.	13.9	918
14	European Society of Cardiology: Cardiovascular Disease Statistics 2017. <i>European Heart Journal</i> , 2018, 39, 508-579.	1.0	595
15	Dronedaronone in High-Risk Permanent Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2011, 365, 2268-2276.	13.9	547
16	ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. <i>European Heart Journal</i> , 2017, 38, ehw149.	1.0	511
17	2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. <i>Europace</i> , 2021, 23, 1612-1676.	0.7	494
18	Noncardiac Comorbidities in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2281-2293.	1.2	424

#	ARTICLE	IF	CITATIONS
19	Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. <i>European Heart Journal</i> , 2011, 32, 1854-1864.	1.0	343
20	Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 1864-1872.	1.0	303
21	Extensive Troponin I and T Modification Detected in Serum From Patients With Acute Myocardial Infarction. <i>Circulation</i> , 2000, 102, 1221-1226.	1.6	282
22	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014, 16, 308-319.	0.7	280
23	2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2017, 70, 50.	0.4	280
24	Prognostic Value of Microvascular Obstruction and Infarct Size, as Measured by CMR in STEMI Patients. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 930-939.	2.3	271
25	Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy. <i>Circulation: Heart Failure</i> , 2015, 8, 71-78.	1.6	238
26	Excitation-Transcription Coupling Mediated by Zinc Influx through Voltage-dependent Calcium Channels. <i>Journal of Biological Chemistry</i> , 1995, 270, 2473-2477.	1.6	215
27	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	1.2	205
28	Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12® rapid analyzer: The VERIFY Thrombosis risk ASsessment (VERITAS) study. <i>Thrombosis Research</i> , 2007, 119, 277-284.	0.8	198
29	Relationship Between Intracellular Calcium and Contractile Force in Stunned Myocardium. <i>Circulation Research</i> , 1995, 76, 1036-1048.	2.0	174
30	Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. <i>European Heart Journal</i> , 2015, 36, 112-119.	1.0	154
31	Frequency and Significance of Troponin T Elevation in Acute Ischemic Stroke. <i>American Journal of Cardiology</i> , 2007, 99, 108-112.	0.7	148
32	Tumor Necrosis Factor- $\alpha$ Antagonists Improve Aortic Stiffness in Patients With Inflammatory Arthropathies. <i>Hypertension</i> , 2010, 55, 333-338.	1.3	144
33	Effect of Intravenous FX06 as an Adjunct to Primary Percutaneous Coronary Intervention for Acute ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2009, 53, 720-729.	1.2	143
34	Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. <i>European Heart Journal</i> , 2014, 35, 224-232.	1.0	140
35	Corrigendum to: "Guidelines for the management of atrial fibrillation" [European Heart Journal (2010) 31, 2369-2429 and EP-Europace (2010) 12, 1360-1420]. <i>European Heart Journal</i> , 2011, 32, 1172-1172.	1.0	133
36	High-Sensitivity Troponin T and Risk Stratification in Patients With Atrial Fibrillation During Treatment With Apixaban or Warfarin. <i>Journal of the American College of Cardiology</i> , 2014, 63, 52-61.	1.2	133

#	ARTICLE	IF	CITATIONS
37	Effect of 1-year anti-TNF- $\alpha$ therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. <i>American Journal of Hypertension</i> , 2012, 25, 644-650.	1.0	126
38	Renin-Angiotensin Blockade Combined With Natriuretic Peptide System Augmentation. <i>Circulation: Heart Failure</i> , 2013, 6, 594-605.	1.6	117
39	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial. <i>Circulation: Heart Failure</i> , 2018, 11, e004962.	1.6	117
40	How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?. <i>Journal of Cardiac Failure</i> , 2004, 10, 297-303.	0.7	110
41	High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 625-634.	1.6	110
42	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017, 38, ehw069.	1.0	106
43	Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 812-817.	0.5	101
44	Troponin I in acute decompensated heart failure: insights from the ASCEND-HF study. <i>European Journal of Heart Failure</i> , 2012, 14, 1257-1264.	2.9	101
45	Integrating new approaches to atrial fibrillation management: the 6th AFNET/EHRA Consensus Conference. <i>Europace</i> , 2018, 20, 395-407.	0.7	95
46	Androgenic Anabolic Steroid Abuse and the Cardiovascular System. <i>Handbook of Experimental Pharmacology</i> , 2009, , 411-457.	0.9	94
47	The myth of "stable" coronary artery disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 9-21.	6.1	89
48	Mechanism of Troponin Elevations in Patients With Acute Ischemic Stroke. <i>American Journal of Cardiology</i> , 2007, 99, 867-870.	0.7	84
49	Serum uric acid is associated with mortality and heart failure hospitalizations in patients with complicated myocardial infarction: findings from the High-Risk Myocardial Infarction Database Initiative. <i>European Journal of Heart Failure</i> , 2015, 17, 1144-1151.	2.9	84
50	Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial. <i>European Heart Journal</i> , 2014, 35, 2516-2523.	1.0	83
51	Enhanced platelet/endothelial activation in depressed patients with acute coronary syndromes. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 563-567.	0.5	79
52	Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight. <i>Circulation</i> , 2019, 139, 2292-2300.	1.6	78
53	Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. <i>European Journal of Heart Failure</i> , 2016, 18, 482-489.	2.9	74
54	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2016, 38, ehv643.	1.0	69

#	ARTICLE	IF	CITATIONS
55	Assessment of Bleeding Events in Clinical Trials—Proposal of a New Classification. <i>American Journal of Cardiology</i> , 2007, 99, 288-290.	0.7	68
56	A new automatic algorithm for quantification of myocardial infarction imaged by late gadolinium enhancement cardiovascular magnetic resonance: experimental validation and comparison to expert delineations in multi-center, multi-vendor patient data. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, 27.	1.6	67
57	COPD Predicts Mortality in HF: The Norwegian Heart Failure Registry. <i>Journal of Cardiac Failure</i> , 2010, 16, 225-229.	0.7	65
58	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622	2.9	65
59	Association of platelet responsiveness with clopidogrel metabolism: Role of compliance in the assessment of "resistance". <i>American Heart Journal</i> , 2009, 158, 925-932.	1.2	64
60	'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 629-630.	0.5	62
61	Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. <i>European Heart Journal</i> , 2016, 37, 747-754.	1.0	62
62	The cancer patient and cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 2290-2309.	2.9	62
63	Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 27, 48-56.	1.0	59
64	Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. <i>European Heart Journal</i> , 2010, 31, 227-235.	1.0	59
65	Current role of neprilysin inhibitors in hypertension and heart failure. , 2014, 144, 41-49.		59
66	Clinical outcomes of patients with diabetes and atrial fibrillation treated with apixaban: results from the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 86-94.	1.4	59
67	Heat Stress Impacts on Cardiac Mortality in Nepali Migrant Workers in Qatar. <i>Cardiology</i> , 2019, 143, 37-48.	0.6	58
68	Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients. <i>Fundamental and Clinical Pharmacology</i> , 2008, 22, 315-321.	1.0	57
69	Fatty Acid Binding Protein 4 Is Associated with Carotid Atherosclerosis and Outcome in Patients with Acute Ischemic Stroke. <i>PLoS ONE</i> , 2011, 6, e28785.	1.1	56
70	Relation of Cardiac Troponin I Measurements at 24 and 48 Hours to Magnetic Resonance—Determined Infarct Size in Patients With ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2009, 104, 1472-1477.	0.7	54
71	Neurohormonal Blockade in Heart Failure. <i>Cardiac Failure Review</i> , 2017, 03, 19.	1.2	53
72	Randomized evaluation of beta blocker and ACE-inhibitor/angiotensin receptor blocker treatment in patients with myocardial infarction with non-obstructive coronary arteries (MINOCA-BAT): Rationale and design. <i>American Heart Journal</i> , 2021, 231, 96-104.	1.2	49

#	ARTICLE	IF	CITATIONS
73	Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical managementâ€”a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2017, 38, ehv676.	1.0	48
74	Time Course of Degradation of Cardiac Troponin I in Patients With Acute ST-Elevation Myocardial Infarction. <i>Circulation Research</i> , 2006, 99, 1141-1147.	2.0	47
75	Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?. <i>European Heart Journal</i> , 2013, 34, 1630-1635.	1.0	47
76	Multi-vendor, multicentre comparison of contrast-enhanced SSFP and T2-STIR CMR for determining myocardium at risk in ST-elevation myocardial infarction. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 744-753.	0.5	47
77	Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 171-180.	1.4	46
78	Increased heart rate variability during nondirective meditation. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 773-780.	0.8	45
79	Non-vitamin K oral anticoagulants in â€˜valvularâ€™™ atrial fibrillation: a call for action. <i>Europace</i> , 2016, 18, 1-3.	0.7	44
80	Pathophysiology, Diagnosis, and Management of the No-Reflow Phenomenon. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 589-597.	1.3	44
81	Management and 1â€Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELDâ€AF Registry. <i>Journal of the American Heart Association</i> , 2019, 8, e010510.	1.6	44
82	Increased soluble platelet / endothelial cellular adhesion molecule-1 and osteonectin levels in patients with severe congestive heart failure. Independence of disease etiology, and antecedent aspirin therapy. <i>European Journal of Heart Failure</i> , 1999, 1, 243-249.	2.9	43
83	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2015, 17, 194-206.	0.7	41
84	The heart failure burden of type 2 diabetes mellitusâ€”a review of pathophysiology and interventions. <i>Heart Failure Reviews</i> , 2018, 23, 303-323.	1.7	41
85	Aspirin inhibits surface glycoprotein IIb/IIIa, P-selectin, CD63, and CD107a receptor expression on human platelets. <i>Blood Coagulation and Fibrinolysis</i> , 2003, 14, 249-253.	0.5	40
86	Predictors of early dyspnoea relief in acute heart failure and the association with 30â€day outcomes: findings from ASCENDâ€HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	2.9	39
87	â€Ten Commandmentsâ€™™ of 2016 ESC Guidelines for the management of atrial fibrillation. <i>European Heart Journal</i> , 2016, 37, 2853-2853.	1.0	38
88	ESC Core Curriculum for the Cardiologist. <i>European Heart Journal</i> , 2020, 41, 3605-3692.	1.0	38
89	Early Prediction of Increased Arterial Stiffness in Patients with Chronic Inflammation: A 15-year Followup Study of 108 Patients with Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 606-612.	1.0	37
90	Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation: An ARISTOTLE Substudy. <i>Clinical Chemistry</i> , 2015, 61, 368-378.	1.5	37

#	ARTICLE	IF	CITATIONS
91	New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention?. <i>Atherosclerosis</i> , 2021, 319, 51-61.	0.4	37
92	Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction. <i>Annals of Internal Medicine</i> , 2022, 175, 101-113.	2.0	37
93	NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1946-1950.	0.5	36
94	Viewpoint: Central adjudication of myocardial infarction in outcome-driven clinical trials â€“ Common patterns in TRITON, RECORD, and PLATO?. <i>Thrombosis and Haemostasis</i> , 2012, 108, 412-414.	1.8	36
95	Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy. <i>Thrombosis Research</i> , 2004, 113, 197-204.	0.8	35
96	Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial. <i>European Heart Journal</i> , 2015, 36, ehv447.	1.0	35
97	Time-resolved tracking of the atrioventricular plane displacement in Cardiovascular Magnetic Resonance (CMR) images. <i>BMC Medical Imaging</i> , 2017, 17, 19.	1.4	35
98	Health Care Professionalsâ€™ Perceptions of Home Telemonitoring in Heart Failure Care: Cross-Sectional Survey. <i>Journal of Medical Internet Research</i> , 2019, 21, e10362.	2.1	35
99	Cardiac troponin I for prediction of clinical outcomes and cardiac function through 3-month follow-up after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2015, 169, 257-265.e1.	1.2	33
100	Prevalence of diastolic dysfunction as a possible cause of dyspnea in the elderly. <i>American Journal of Medicine</i> , 2005, 118, 25-31.	0.6	31
101	Sample Size in Clinical Cardioprotection Trials Using Myocardial Salvage Index, Infarct Size, or Biochemical Markers as Endpoint. <i>Journal of the American Heart Association</i> , 2016, 5, e002708.	1.6	31
102	Patients with metabolic syndrome exhibit higher platelet activity than those with conventional risk factors for vascular disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2008, 25, 207-213.	1.0	30
103	ESC guidelines adherence is associated with improved survival in patients from the Norwegian Heart Failure Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 31-36.	1.4	30
104	Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrel. <i>Thrombosis and Haemostasis</i> , 2012, 107, 338-345.	1.8	29
105	Combined angiotensin receptor blockade and neprilysin inhibition attenuates angiotensin-II mediated renal cellular collagen synthesis. <i>International Journal of Cardiology</i> , 2015, 186, 104-105.	0.8	29
106	Effects of Magnesium Supplementation in a Porcine Model of Myocardial Ischemia and Reperfusion. <i>Journal of Cardiovascular Pharmacology</i> , 1994, 24, 603-611.	0.8	28
107	Characteristics of patients with atrial fibrillation prescribed antiplatelet monotherapy compared with those on anticoagulants: insights from the GARFIELD-AF registry. <i>European Heart Journal</i> , 2018, 39, 464-473.	1.0	28
108	Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure. <i>Clinical Research in Cardiology</i> , 2017, 106, 711-721.	1.5	27

#	ARTICLE	IF	CITATIONS
109	Antithrombotic therapy and major adverse limb events in patients with chronic lower extremity arterial disease: systematic review and meta-analysis from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy in Collaboration with the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 86-93.	1.4	27
110	Usefulness of Natriuretic Peptide Testing for Long-Term Risk Assessment Following Acute Ischemic Stroke. <i>American Journal of Cardiology</i> , 2009, 104, 287-291.	0.7	26
111	Activated Leukocyte Cell Adhesion Molecule and Prognosis in Acute Ischemic Stroke. <i>Stroke</i> , 2011, 42, 2453-2458.	1.0	26
112	Comparative efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) for cardiovascular outcomes in type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. <i>Heart Failure Reviews</i> , 2021, 26, 1421-1435.	1.7	26
113	Escitalopram, but Not Its Major Metabolites, Exhibits Antiplatelet Activity in Humans. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 172-177.	0.7	25
114	Pharmacological conversion of recent-onset atrial fibrillation: A systematic review. <i>Scandinavian Cardiovascular Journal</i> , 2013, 47, 2-10.	0.4	25
115	Clinical review: Impact of statin substitution policies on patient outcomes. <i>Annals of Medicine</i> , 2009, 41, 242-256.	1.5	24
116	Gender differences among Norwegian patients with heart failure. <i>International Journal of Cardiology</i> , 2011, 146, 354-358.	0.8	24
117	Relationship between left ventricular ejection fraction and mortality after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>International Journal of Cardiology</i> , 2018, 272, 260-266.	0.8	24
118	Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. <i>Fundamental and Clinical Pharmacology</i> , 2011, 25, 511-517.	1.0	23
119	Comorbidities and Polypharmacy. <i>Heart Failure Clinics</i> , 2014, 10, 367-372.	1.0	23
120	The PLATO trial: do you believe in magic?. <i>European Heart Journal</i> , 2010, 31, 764-767.	1.0	22
121	The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events. <i>Europace</i> , 2020, 22, 195-204.	0.7	22
122	Influence of receptor selectivity on benefits from SGLT2 inhibitors in patients with heart failure: a systematic review and head-to-head comparative efficacy network meta-analysis. <i>Clinical Research in Cardiology</i> , 2022, 111, 428-439.	1.5	22
123	The l-arginine/asymmetric dimethylarginine ratio is improved by anti-Tumor Necrosis Factor $\alpha$ therapy in inflammatory arthropathies. Associations with aortic stiffness. <i>Atherosclerosis</i> , 2012, 225, 160-165.	0.4	21
124	Clinical benefit of drugs targeting mitochondrial function as an adjunct to reperfusion in ST-segment elevation myocardial infarction: A meta-analysis of randomized clinical trials. <i>International Journal of Cardiology</i> , 2017, 244, 59-66.	0.8	21
125	Design and rationale of the Danish trial of beta-blocker treatment after myocardial infarction without reduced ejection fraction: study protocol for a randomized controlled trial. <i>Trials</i> , 2020, 21, 415.	0.7	21
126	Carvedilol Compared With Metoprolol Succinate in the Treatment and Prognosis of Patients With Stable Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 887-896.	1.6	20



#	ARTICLE	IF	CITATIONS
127	Extent of Myocardium at Risk for Left Anterior Descending Artery, Right Coronary Artery, and Left Circumflex Artery Occlusion Depicted by Contrast-Enhanced Steady State Free Precession and T2-Weighted Short Tau Inversion Recovery Magnetic Resonance Imaging. <i>Circulation: Cardiovascular Imaging</i> , 2016, 9, .	1.3	20
128	Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin. <i>Stroke</i> , 2017, 48, 3266-3273.	1.0	20
129	BETablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study. <i>American Heart Journal</i> , 2019, 208, 37-46.	1.2	20
130	Antiplatelet Properties of Escitalopram in Patients with the Metabolic Syndrome: A Dose-Ranging In Vitro Study. <i>Neuropsychopharmacology</i> , 2007, 32, 2369-2374.	2.8	19
131	GARFIELD-AF: a worldwide prospective registry of patients with atrial fibrillation at risk of stroke. <i>Future Cardiology</i> , 2021, 17, 19-38.	0.5	19
132	Magnesium deficiency prolongs myocardial stunning in an open-chest swine model. <i>International Journal of Cardiology</i> , 1994, 47, 105-115.	0.8	18
133	Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes. <i>International Journal of Cardiology</i> , 2013, 168, 2510-2517.	0.8	18
134	Epidemiology and long-term outcome in outpatients with chronic heart failure in Northwestern Europe. <i>Heart</i> , 2019, 105, 1252-1259.	1.2	18
135	Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 147-150.	1.4	17
136	Lack of nuclear apoptosis in cardiomyocytes and increased endothelin-1 levels in a rat heart model of myocardial stunning. <i>Basic Research in Cardiology</i> , 2000, 95, 308-315.	2.5	16
137	Echocardiographic indices of left ventricular diastolic dysfunction in 647 individuals with preserved left ventricular systolic function. <i>European Journal of Heart Failure</i> , 2004, 6, 439-447.	2.9	16
138	Dipyridamole Decreases Protease-Activated Receptor and Annexin-V Binding on Platelets of Poststroke Patients with Aspirin Nonresponsiveness. <i>Cerebrovascular Diseases</i> , 2006, 21, 98-105.	0.8	16
139	Rationale and Design of the â€ˆF.I.R.E.â€™™ Study. <i>Cardiology</i> , 2007, 108, 117-123.	0.6	16
140	Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry. <i>Indian Heart Journal</i> , 2018, 70, 828-835.	0.2	16
141	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 782-790.	2.9	16
142	Gender differences in association between uric acid and all-cause mortality in patients with chronic heart failure. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 4.	0.7	15
143	Self-Care Monitoring of Heart Failure Symptoms and Lung Impedance at Home Following Hospital Discharge: Longitudinal Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e15445.	2.1	15
144	Cost-Minimization Analysis for Cardiac Revascularization in 12 Health Care Systems Based on the EuroCMR/SPINS Registries. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 607-625.	2.3	15

#	ARTICLE	IF	CITATIONS
145	Influence of ST-Segment Recovery on Infarct Size and Ejection Fraction in Patients With ST-Segment Elevation Myocardial Infarction Receiving Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2010, 105, 1223-1228.	0.7	14
146	Reduced preload elicits increased LV twist in healthy humans. <i>Clinical Physiology and Functional Imaging</i> , 2011, 31, 382-389.	0.5	14
147	Incremental value of a combination of cardiac troponin T, N-terminal pro-brain natriuretic peptide and C-reactive protein for prediction of mortality in end-stage renal disease. <i>Scandinavian Journal of Urology and Nephrology</i> , 2011, 45, 151-158.	1.4	14
148	B-type natriuretic peptide trumps other prognostic markers in patients assessed for coronary disease. <i>BMC Medicine</i> , 2019, 17, 72.	2.3	14
149	Effects of in vitro exposure of alcohol on surface receptor expression of human platelets. <i>Clinical Physiology and Functional Imaging</i> , 2002, 22, 153-156.	0.5	13
150	Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome. <i>Heart</i> , 2015, 101, 1475-1484.	1.2	13
151	Data on administration of cyclosporine, nicorandil, metoprolol on reperfusion related outcomes in ST-segment Elevation Myocardial Infarction treated with percutaneous coronary intervention. <i>Data in Brief</i> , 2017, 14, 197-205.	0.5	13
152	Patient engagement. <i>European Heart Journal</i> , 2017, 38, 3114-3115.	1.0	13
153	Maximizing scientific knowledge from randomized clinical trials. <i>American Heart Journal</i> , 2010, 159, 937-943.	1.2	12
154	Atrial Fibrillation and Stroke in Patients with Hypertrophic Cardiomyopathy: Important New Insights. <i>Thrombosis and Haemostasis</i> , 2019, 119, 355-357.	1.8	12
155	Impact of time to therapy and presence of collaterals on the efficacy of FX06 in acute ST elevation myocardial infarction: a substudy of the F.I.R.E., the Efficacy of FX06 in the prevention of myocardial reperfusion injury trial. <i>EuroIntervention</i> , 2010, 5, 946-952.	1.4	12
156	Anticoagulants for secondary prevention after acute myocardial infarction: lessons from the past decade. <i>Fundamental and Clinical Pharmacology</i> , 2014, 28, 353-363.	1.0	11
157	Expanding the Evidence Base. <i>American Journal of Therapeutics</i> , 2015, 22, e141-e150.	0.5	11
158	Automatic segmentation of myocardium at risk from contrast enhanced SSFP CMR: validation against expert readers and SPECT. <i>BMC Medical Imaging</i> , 2016, 16, 19.	1.4	11
159	Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 82-92.	1.4	11
160	Atrial fibrillation in cryptogenic stroke and transient ischaemic attack â€œ The Nordic Atrial Fibrillation and Stroke (NOR-FIB) Study: Rationale and design. <i>European Stroke Journal</i> , 2019, 4, 172-180.	2.7	11
161	Comparative effectiveness of loop diuretics on mortality in the treatment of patients with chronic heart failure â€œ A multicenter propensity score matched analysis. <i>International Journal of Cardiology</i> , 2019, 289, 83-90.	0.8	10
162	Consistent platelet inhibition during long-term maintenance-dose clopidogrel therapy among 359 compliant outpatients with documented vascular disease. <i>American Heart Journal</i> , 2007, 153, 371-377.	1.2	9

#	ARTICLE	IF	CITATIONS
163	The association between meteorological events and acute heart failure: New insights from ASCEND-HF. <i>International Journal of Cardiology</i> , 2014, 177, 819-824.	0.8	9
164	Longitudinal left ventricular function is globally depressed within a week of <sc>STEMI</sc>. <i>Clinical Physiology and Functional Imaging</i> , 2018, 38, 1029-1037.	0.5	9
165	Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction?. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2019, 24, 215-224.	1.0	9
166	Biomarkers Associated with Atrial Fibrillation in Patients with Ischemic Stroke: A Pilot Study from the NOR-FIB Study. <i>Cerebrovascular Diseases Extra</i> , 2020, 10, 11-20.	0.5	9
167	Diagnostic Accuracy and Usability of the ECG247 Smart Heart Sensor Compared to Conventional Holter Technology. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-8.	1.1	9
168	Comparison of four different cardiac troponin assays in patients with end-stage renal disease on chronic haemodialysis. <i>Acute Cardiac Care</i> , 2008, 10, 173-180.	0.2	8
169	Increased LV apical untwist during preload reduction in healthy humans: an echocardiographic speckle tracking study during lower body negative pressure. <i>Physiological Reports</i> , 2015, 3, e12330.	0.7	8
170	Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. <i>American Journal of Medicine</i> , 2019, 132, 1431-1440.e7.	0.6	8
171	Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials. <i>Heart Failure Reviews</i> , 2020, 25, 161-171.	1.7	8
172	Pre-hospital One-Hour Troponin in a Low-Prevalence Population of Acute Coronary Syndrome: OUT-ACS study. <i>Open Heart</i> , 2020, 7, e001296.	0.9	8
173	Comparison of a single high-sensitivity cardiac troponin T measurement with the HEART score for rapid rule-out of acute myocardial infarction in a primary care emergency setting: a cohort study. <i>BMJ Open</i> , 2021, 11, e046024.	0.8	8
174	Amyotrophic lateral sclerosis (ALS), a novel rare cause of elevated plasma troponin T levels. <i>Clinical Laboratory</i> , 2011, 57, 615-8.	0.2	8
175	Cardiovascular phenotype of long-term anabolic-androgenic steroid abusers compared with strength-trained athletes. <i>Scandinavian Journal of Medicine and Science in Sports</i> , 2022, 32, 1170-1181.	1.3	8
176	Effects of escalating doses of tirofiban on platelet aggregation and major receptor expression in diabetic patients: Hitting the TARGET in the TENACITY trial?. <i>Thrombosis Research</i> , 2007, 119, 175-181.	0.8	7
177	The relation between electrocardiographic ST-T changes and NT-proBNP in patients with acute ischemic stroke. <i>Scandinavian Cardiovascular Journal</i> , 2007, 41, 294-298.	0.4	7
178	Antiplatelet "resistance"™ and "nonresponders"™: what do these terms <i>really</i> mean?. <i>Fundamental and Clinical Pharmacology</i> , 2009, 23, 11-18.	1.0	7
179	Morphine in myocardial infarction: balancing on the tight rope. <i>European Heart Journal</i> , 2016, 37, 253-255.	1.0	7
180	Spironolactone Treatment and Effect on Survival in Chronic Heart Failure Patients with Reduced Renal Function: A Propensity-Matched Study. <i>CardioRenal Medicine</i> , 2017, 7, 128-136.	0.7	7

#	ARTICLE	IF	CITATIONS
181	Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants. <i>Scandinavian Cardiovascular Journal</i> , 2018, 52, 156-162.	0.4	7
182	The significance of ST-elevation in aVL in anterolateral myocardial infarction: An assessment by cardiac magnetic resonance imaging. <i>Annals of Noninvasive Electrocardiology</i> , 2018, 23, e12580.	0.5	7
183	Left ventricular ejection fraction and adjudicated, cause-specific hospitalizations after myocardial infarction complicated by heart failure or left ventricular dysfunction. <i>American Heart Journal</i> , 2019, 215, 83-90.	1.2	7
184	Mortality and adverse events with brand and generic clopidogrel in the US Food and Drug Administration Adverse Event Reporting System. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 210-215.	1.4	7
185	Prevalence of genetically verified familial hypercholesterolemia among young (<math>\leq 45</math> years) Norwegian patients hospitalized with acute myocardial infarction. <i>Journal of Clinical Lipidology</i> , 2020, 14, 339-345.	0.6	7
186	Do We Really Need Aspirin Loading for STEMI?. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 1221-1238.	1.3	7
187	Atrioventricular plane motion during dobutamine-atropine stress echocardiography: The biphasic response in healthy subjects revisited. <i>Journal of the American Society of Echocardiography</i> , 2000, 13, 885-890.	1.2	6
188	Obstructive sleep apnea: no independent association to troponins. <i>Sleep and Breathing</i> , 2014, 18, 351-358.	0.9	6
189	Administration of the Mitochondrial Permeability Transition Pore Inhibitor, TRO40303, prior to Primary Percutaneous Coronary Intervention, Does Not Affect the Levels of Pro-Inflammatory Cytokines or Acute-Phase Proteins. <i>Cardiology</i> , 2017, 138, 122-132.	0.6	6
190	Electrocardiographic scores of severity and acuteness of myocardial ischemia predict myocardial salvage in patients with anterior ST-segment elevation myocardial infarction. <i>Journal of Electrocardiology</i> , 2018, 51, 195-202.	0.4	6
191	Cardiac Magnetic Resonance Evaluation of the Extent of Myocardial Injury in Patients with Inferior ST Elevation Myocardial Infarction and Concomitant ST Depression in Leads V1-V3: Analysis from the MITOCARE Study. <i>Cardiology</i> , 2018, 140, 178-185.	0.6	6
192	All-Cause Mortality and Cardiovascular Outcomes With Non-Vitamin K Oral Anticoagulants Versus Warfarin in Patients With Heart Failure in the Food and Drug Administration Adverse Event Reporting System. <i>American Journal of Therapeutics</i> , 2019, 26, e671-e678.	0.5	6
193	Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 227-235.	1.4	6
194	Cardioversion in patients with newly diagnosed non-valvular atrial fibrillation: observational study using prospectively collected registry data. <i>BMJ, The</i> , 2021, 375, e066450.	3.0	6
195	MVnet: automated time-resolved tracking of the mitral valve plane in CMR long-axis cine images with residual neural networks: a multi-center, multi-vendor study. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2021, 23, 137.	1.6	6
196	Effect of coronary thrombolysis on the plasma concentration of osteonectin (SPARC, BM40) in patients with acute myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2000, 10, 197-202.	1.0	5
197	Platelets and Thrombolysis: Cooperation or Contrariety?. <i>Cardiology</i> , 2001, 1, 281-290.	0.3	5
198	Regional LV deformation in healthy individuals during isovolumetric contraction and ejection phases assessed by 2D speckle tracking echocardiography. <i>Clinical Physiology and Functional Imaging</i> , 2012, 32, 372-379.	0.5	5

#	ARTICLE	IF	CITATIONS
199	Cost Effectiveness of Drug-Eluting Stents as Compared With Bare Metal Stents in Patients With Coronary Artery Disease. <i>American Journal of Therapeutics</i> , 2013, 20, 596-601.	0.5	5
200	Fatal Sepsis and Systemic Inflammatory Response Syndrome After Off-Label Prasugrel. <i>American Journal of Therapeutics</i> , 2014, 21, e229-e233.	0.5	5
201	Assessment of Right Ventricular Afterload in COPD. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2016, 13, 176-185.	0.7	5
202	Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 238, 97-104.	0.8	5
203	Myocardium at risk assessed by electrocardiographic scores and cardiovascular magnetic resonance - a MITOCARE substudy. <i>Journal of Electrocardiology</i> , 2017, 50, 725-731.	0.4	5
204	How does the TRS 2 <sup>Â</sup> P score relate to real-world patients?. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 72-74.	1.4	5
205	Gender but not diabetes, hypertension or smoking affects infarct evolution in ST-elevation myocardial infarction patients â€” data from the CHILL-MI, MITOCARE and SOCCER trials. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 161.	0.7	5
206	No association between APOE genotype and lipid lowering with cognitive function in a randomized controlled trial of evolocumab. <i>PLoS ONE</i> , 2022, 17, e0266615.	1.1	5
207	Cell Adhesion Molecules in Cardiovascular Pathology â€” A Glance into the Future?. <i>Cardiology</i> , 2001, 1, 225-235.	0.3	4
208	Troponin I degradation in serum of patients with acute ischemic stroke. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2011, 71, 74-80.	0.6	4
209	Relation of cardiac troponin I and microvascular obstruction following ST-elevation myocardial infarction. <i>Acute Cardiac Care</i> , 2011, 13, 48-51.	0.2	4
210	Prasugrel. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2013, 6, 253-254.	0.9	4
211	Myeloid-related protein-8/14 and C-reactive protein in individuals evaluated for obstructive sleep apnea. <i>Sleep Medicine</i> , 2014, 15, 762-768.	0.8	4
212	Cost-effectiveness of antiplatelet drugs after percutaneous coronary intervention. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2016, 2, 52-57.	1.8	4
213	European Heart Journal-Cardiovascular Pharmacotherapy in 2016: entering a new level of international recognition. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 3-4.	1.4	4
214	Correlation of anteroseptal ST elevation with myocardial infarction territories through cardiovascular magnetic resonance imaging. <i>Journal of Electrocardiology</i> , 2018, 51, 563-568.	0.4	4
215	On-label reduced doses of non-vitamin K anticoagulants prove safe and efficient; yet how to ensure the correct dose for the right patient?. <i>European Heart Journal</i> , 2019, 40, 1501-1503.	1.0	4
216	Inferior ST-Elevation Myocardial Infarction Presenting When Urgent Primary Percutaneous Coronary Intervention Is Unavailable: Should We Adhere to Current Guidelines?. <i>Cardiovascular Drugs and Therapy</i> , 2020, 34, 865-870.	1.3	4

#	ARTICLE	IF	CITATIONS
217	Efficacy of Long-Term Oral Beta-Blocker Therapy in Patients Who Underwent Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction With Preserved Left Ventricular Ejection Fraction: A Systematic Review and Meta-analysis. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 87-93.	0.8	4
218	The Role of ECG in the Diagnosis and Risk Stratification of Acute Coronary Syndromes: an Old but Indispensable Tool. <i>Current Cardiology Reports</i> , 2022, 24, 109-118.	1.3	4
219	Cryptogenic stroke and TIA: Suggested diagnostic approach while waiting for evaluation and treatment guidelines. <i>Acta Neurologica Scandinavica</i> , 2022, 145, 641-646.	1.0	4
220	Aggrenox <sup>®</sup> (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events. <i>Cardiology</i> , 2002, 2, 93-104.	0.3	3
221	End of story? Studies on prevention of reperfusion injury encounter perpetual defeats. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 46-47.	1.4	3
222	In Current Clinical Practice, after Percutaneous Coronary Intervention for Acute Myocardial Infarction, Are Î²-Blockers Prescribed for Heart Failure or as Secondary Prevention? A Pilot Study. <i>Cardiology</i> , 2018, 140, 152-154.	0.6	3
223	Challenging Anticoagulation in Advanced Renal Failure. <i>American Journal of Medicine</i> , 2019, 132, 1258-1259.	0.6	3
224	Worst lead ST deviation and resolution of ST elevation at one hour for prediction of myocardial salvage, infarct size, and microvascular obstruction in patients with STâ€elevation myocardial infarction treated with primary percutaneous coronary intervention. <i>Annals of Noninvasive Electrocardiology</i> , 2020, 25, e12784.	0.5	3
225	Is RBBB the new LBBB? Are we going to repeat the same mistakes?. <i>Journal of Electrocardiology</i> , 2021, 65, 34-36.	0.4	3
226	Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. <i>Thrombosis and Haemostasis</i> , 2008, 100, 314-8.	1.8	3
227	Changes in diagnosing non-ST-segment elevation myocardial infarction after the introduction of a new high-sensitivity cardiac troponin T assay: a single-centre experience. <i>Clinical Laboratory</i> , 2012, 58, 1029-36.	0.2	3
228	Selective Serotonin Reuptake Inhibitors: Future Treatment of Vascular Disease?. <i>Cardiology</i> , 2001, 1, 332-340.	0.3	2
229	Rheumatic mitral valve stenosis mimicking advanced lung cancer. <i>Heart and Vessels</i> , 2007, 22, 345-348.	0.5	2
230	Editorial: Sudden cardiac death â€“ the challenge to cardiology. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 535-537.	1.0	2
231	A window into your heart: taking cardiac troponin to the next level. <i>Biomarkers in Medicine</i> , 2010, 4, 889-894.	0.6	2
232	Correlation of ST changes in leads V4â€“V6 to area of ischemia by CMR in inferior STEMI. <i>Scandinavian Cardiovascular Journal</i> , 2018, 52, 189-195.	0.4	2
233	Appropriateness of anteroseptal myocardial infarction nomenclature evaluated by late gadolinium enhancement cardiovascular magnetic resonance imaging. <i>Journal of Electrocardiology</i> , 2018, 51, 218-223.	0.4	2
234	Angiotensin receptor neprilysin inhibition for the treatment of hypertension: the neglected child in cardiovascular pharmacotherapy. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 122-123.	1.4	2

#	ARTICLE	IF	CITATIONS
235	Does Ivabradine Decrease Cardiovascular Deaths in Heart Failure Patients?. American Journal of Medicine, 2020, 133, 347-351.	0.6	2
236	Use of Non-vitamin K Antagonist Oral Anticoagulants for Stroke Prevention across the Stroke Spectrum: Progress and Prospects. Thrombosis and Haemostasis, 2021, 121, 716-730.	1.8	2
237	The Association of Smoking with Hospitalization and Mortality Differs According to Sex in Patients with Heart Failure Following Myocardial Infarction. Journal of Women's Health, 2022, 31, 310-320.	1.5	2
238	Performance of the Novel Observation Group Criteria of the European Society of Cardiology (ESC) 0/1â€œHour Algorithm in a Lowâ€œRisk Population. Journal of the American Heart Association, 2022, 11, e024927.	1.6	2
239	Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances. Kardiologia Polska, 2022, 80, 741-749.	0.3	2
240	Cholesterol and peripheral vascular disease: A neglected topic?. Scandinavian Cardiovascular Journal, 2007, 41, 136-137.	0.4	1
241	Asymptomatic Myocardial Infarction prior to Ischemic Stroke?. Cerebrovascular Diseases, 2007, 24, 318-318.	0.8	1
242	Interpreting clinical trials: the â€œBeautifulâ€œ™ case. Fundamental and Clinical Pharmacology, 2009, 23, 261-262.	1.0	1
243	Corrigendum to â€œESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008â€œ™ [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. European Journal of Heart Failure, 2010, 12, 416-416.	2.9	1
244	Effects of FX06 In Vitro on Platelet, Coagulation, and Fibrinolytic Biomarkers in Volunteers and Patients With Documented Coronary Artery Disease. American Journal of Therapeutics, 2014, 21, 91-98.	0.5	1
245	Heart rate prediction of outcome in heart failure following myocardial infarction depend on heart rhythm status an analysis from the high-risk myocardial infarction database initiative. International Journal of Cardiology, 2017, 249, 274-281.	0.8	1
246	Type 2 Diabetes and Heart Failure - More Scrutiny Wanted!. Cardiology, 2018, 139, 37-39.	0.6	1
247	Cardioversion Safety â€œ Are We Doing Enough?. Cardiology, 2020, 145, 740-745.	0.6	1
248	The Times They Are A-Changin'Â: Antithrombotic strategies in patients with acute coronary syndrome undergoing coronary stenting who have concomitant atrial fibrillation. European Journal of Internal Medicine, 2021, 88, 21-22.	1.0	1
249	Modulating the Intensity of Oral Anticoagulation Therapy with Direct Oral Anticoagulants: Feasible or Not?. American Journal of Cardiovascular Drugs, 2021, , 1.	1.0	1
250	Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDISâ€œADONIS trials. Clinical Cardiology, 2022, 45, 101-109.	0.7	1
251	Editorsâ€œ™ Introductory Note. Cardiology, 2001, 1, 241-241.	0.3	0
252	Biomarkers and Exercise Training: A Possible Missing Link between Physical Activity and Mortality Benefit in Patients with Heart Failure. Cardiology, 2001, 1, 110-124.	0.3	0

#	ARTICLE	IF	CITATIONS
253	Welcome Address " from the Editors. <i>Cardiology</i> , 2001, 1, 1-1.	0.3	0
254	FCP welcomes <i>Cardiovascular Pharmacology and Drug Therapy</i> . <i>Fundamental and Clinical Pharmacology</i> , 2007, 21, 457-457.	1.0	0
255	Telmisartan and Stroke Reduction in the ONTARGET Trial: Benefit beyond Blood Pressure Lowering?. <i>Cerebrovascular Diseases</i> , 2008, 26, 563-564.	0.8	0
256	Hotline sessions of the 30th European Congress of Cardiology. <i>European Heart Journal</i> , 2009, 30, 1151-1151.	1.0	0
257	Optimal Time-Point of ST-Segment Assessment for Risk-Stratification Following Primary Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2010, 105, 1648-1649.	0.7	0
258	Conclusion. <i>Advances in Cardiology</i> , 2012, 47, 165-165.	2.6	0
259	Introduction. <i>Advances in Cardiology</i> , 2012, 47, 1-4.	2.6	0
260	Effect of Aliskiren and Valsartan Combination Versus Aliskiren Monotherapy on Hemostatic Biomarkers in Hypertensive Diabetics. <i>American Journal of Therapeutics</i> , 2014, 21, 482-490. <a href="#">CardioPulse Articles * The National Cardiac Societies of the European Society of Cardiology</a>	0.5	0
261	Cardiology update 2015: a tradition in excellent postgraduate education supported by the European Society of Cardiology * Sir Donald Ross, pioneer aortic valve surgeon * Plans of the British Cardiovascular Society to seek patients' views on research may aid research grant applications * Dr Hector Bueno reviews the proposed criteria of the German Society of Cardiology for the Establishment of Chest Pain Units1 in th. <i>European Heart Journal</i> , 2015, 36, 1278-1283.	1.0	0
262	Author's response to: letter to the editor. <i>Heart Failure Reviews</i> , 2018, 23, 819-819.	1.7	0
263	Peripheral arterial disease and limb salvage: a new arena for the cardiologist. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 136-137.	1.4	0
264	Editor's Note. <i>Cardiology</i> , 2019, 142, 1-1.	0.6	0
265	Ivabradine for heart failure: regulatory differences in Europe and United States. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 119-121.	1.4	0
266	The perils of data sharing, meta-analyses, and estimating cardiovascular risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e55-e57.	1.4	0
267	Risk profile, antithrombotic treatment and clinical outcomes of patients in Nordic countries with atrial fibrillation " results from the GARFIELD-AF registry. <i>Annals of Medicine</i> , 2021, 53, 485-494.	1.5	0
268	Icons in Cardiology. <i>Cardiology</i> , 2021, 146, 667.	0.6	0
269	The debated issue of direct oral anticoagulants correct dosing: When even the reviewer is confused. <i>European Journal of Internal Medicine</i> , 2021, 90, 125-126.	1.0	0
270	Re: Antikoagulasjon og akronymer " NOAK eller DOAK?. <i>Tidsskrift for Den Norske Lægeforening</i> , 2017, 137, 424-424.	0.2	0



#	ARTICLE	IF	CITATIONS
271	Response to the editor. Heart Failure Reviews, 2018, 23, 819.	1.7	0
272	Characteristics, treatment patterns, and residual cardiovascular risk of patients with a first acute myocardial infarction: A nationwide population-based cohort study in Norway. Fundamental and Clinical Pharmacology, 2021, , .	1.0	0